- Home
- QLGN vs ENSC Comparison
QLGN vs ENSC Comparison
Compare QLGN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- ENSC
- Stock Information
- Founded
- QLGN 1996
- ENSC 2003
- Country
- QLGN United States
- ENSC United States
- Employees
- QLGN N/A
- ENSC N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- ENSC Health Care
- Exchange
- QLGN Nasdaq
- ENSC Nasdaq
- Market Cap
- QLGN 4.7M
- ENSC 5.2M
- IPO Year
- QLGN N/A
- ENSC N/A
- Fundamental
- Price
- QLGN $2.80
- ENSC $2.24
- Analyst Decision
- QLGN
- ENSC
- Analyst Count
- QLGN 0
- ENSC 0
- Target Price
- QLGN N/A
- ENSC N/A
- AVG Volume (30 Days)
- QLGN 2.5M
- ENSC 92.0K
- Earning Date
- QLGN 07-21-2025
- ENSC 08-13-2025
- Dividend Yield
- QLGN N/A
- ENSC N/A
- EPS Growth
- QLGN N/A
- ENSC N/A
- EPS
- QLGN N/A
- ENSC N/A
- Revenue
- QLGN N/A
- ENSC $6,224,081.00
- Revenue This Year
- QLGN N/A
- ENSC N/A
- Revenue Next Year
- QLGN N/A
- ENSC $1,381.48
- P/E Ratio
- QLGN N/A
- ENSC N/A
- Revenue Growth
- QLGN N/A
- ENSC 256.35
- 52 Week Low
- QLGN $2.74
- ENSC $1.62
- 52 Week High
- QLGN $13.50
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- QLGN 35.34
- ENSC 52.50
- Support Level
- QLGN $2.77
- ENSC $2.08
- Resistance Level
- QLGN $3.29
- ENSC $2.27
- Average True Range (ATR)
- QLGN 0.53
- ENSC 0.17
- MACD
- QLGN -0.06
- ENSC 0.01
- Stochastic Oscillator
- QLGN 1.65
- ENSC 62.79
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.